

Sandra V Navarra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7226294/publications.pdf>

Version: 2024-02-01

45
papers

4,234
citations

361045

20
h-index

315357

38
g-index

45
all docs

45
docs citations

45
times ranked

3681
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
2	“Not at target”™: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
3	P258â€fSecukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
4	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational <i>study</i>. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9
5	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2021, 3, e517-e531.	2.2	26
6	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2070-2080.	6.3	268
7	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	0.9	11
8	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. <i>RMD Open</i> , 2021, 7, e001600.	1.8	18
9	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021, 30, 1790-1798.	0.8	1
10	Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1106-1111.	0.9	10
11	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. <i>RMD Open</i> , 2021, 7, e001747.	1.8	10
12	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
13	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. <i>Rheumatology</i> , 2020, 59, 1325-1334.	0.9	40
14	Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. <i>Rheumatology</i> , 2020, 59, 281-291.	0.9	55
15	Lupus education for physicians and patients in a resource-limited setting. <i>Clinical Rheumatology</i> , 2020, 39, 697-702.	1.0	5
16	Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 197-202.	0.9	12
17	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e24-e30.	2.2	45
18	P250â€fEffect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. <i>Rheumatology</i> , 2020, 59, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	0.9	12
20	<p></p>Practice Advisory on the Appropriate Use of NSAIDs in Primary Care<p></p>. Journal of Pain Research, 2020, Volume 13, 1925-1939.	0.8	11
21	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <sc>SLE</sc>: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	2.3	30
22	Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. International Journal of Rheumatic Diseases, 2019, 22, 1933-1936.	0.9	5
23	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatology, The, 2019, 1, e95-e102.	2.2	65
24	OP0246-...ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .		0
25	OP0330-...#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0
26	THU0253-...EFFECT OF GLUCOCORTICOID ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0
27	LB0006-...SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL. , 2019, , .		1
28	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	0.9	24
29	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212687.	0.5	193
30	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	2.3	48
31	Strong viral associations with SLE among Filipinos. Lupus Science and Medicine, 2017, 4, e000214.	1.1	24
32	Development and implementation of Models of Care for musculoskeletal conditions in middle-income and low-income Asian countries. Best Practice and Research in Clinical Rheumatology, 2016, 30, 398-419.	1.4	13
33	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases, 2016, 75, 1615-1621.	0.5	421
34	Biologic therapies in systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2015, 18, 146-153.	0.9	11
35	Risk of tuberculosis with anti-tumor necrosis factor- therapy: substantially higher number of patients at risk in <sc>A</sc>sia. International Journal of Rheumatic Diseases, 2014, 17, 291-298.	0.9	63
36	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.5	558

#	ARTICLE	IF	CITATIONS
37	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 625-636.	0.9	34
38	Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1833-1838.	0.5	350
39	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2011, 377, 721-731.	6.3	1,629
40	Lupus in the developing world “ is it any different?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 643-655.	1.4	80
41	Risk factors for avascular necrosis among Filipino patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 141-147.	0.9	5
42	Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2008, 18, 161-164.	0.9	20
43	Pulmonary arterial hypertension among Filipino patients with connective tissue diseases. <i>Modern Rheumatology</i> , 2007, 17, 224-227.	0.9	3
44	A survey of psychosocial attributes of Filipino patients with systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 107-111.	0.2	4
45	Risk factors for stroke among Filipino patients with systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2005, 8, 19-22.	0.2	0